Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)

Bradley Monk; Nicole Concin; Debra Richardson; Isabelle Ray-Coquard; Bhavana Pothuri; Christian Marth; Patricia Bernardo; Robert Burger; Ellie Im; Wassim Aldairy; Robert Coleman; Mansoor Mirza

doi:10.1016/S0090-8258(22)01541-4

Back

Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)

Journal article

Peer reviewed

Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)

Bradley Monk, Nicole Concin, Debra Richardson, Isabelle Ray-Coquard, Bhavana Pothuri, Christian Marth, Patricia Bernardo, Robert Burger, Ellie Im, Wassim Aldairy, …

Gynecologic oncology, Vol.166, p.S166

08/2022

DOI: https://doi.org/10.1016/S0090-8258(22)01541-4

Metrics

5 Record Views

Details

Title: Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)
Creators: Bradley Monk
Nicole Concin
Debra Richardson
Isabelle Ray-Coquard
Bhavana Pothuri
Christian Marth
Patricia Bernardo
Robert Burger
Ellie Im
Wassim Aldairy
Robert Coleman
Mansoor Mirza
Publication Details: Gynecologic oncology, Vol.166, p.S166
Identifiers: 991005969004502656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)

Related links

Metrics

Details